Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

ept.  Patients should be monitored for changes in their lipid profiles and provided with medical treatment if warranted.  Hypersensitivity reactions associated with rilonacept administration have been rare.  Please see the full Prescribing Information for ARCALYST® (rilonacept), available online at www.regeneron.com/ARCALYST-fpi.pdf.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST  Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing dr
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Cyberonics, Inc. (NASDAQ: ... ANTHEM-HF clinical study.  Results of the study presented ... major European cardiology congress and concurrently published by ... Autonomic Regulation Therapy (ART) in patients with moderate ... function is safe, improves the heart,s ability to ...
(Date:9/2/2014)... Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... agreement to purchase the Interventional business of Bayer ... Scientific to offer physicians and healthcare systems a ... vascular conditions. The addition of the ... supports the Boston Scientific strategy to provide a ...
(Date:9/2/2014)... 2, 2014  Based on its recent analysis ... Frost & Sullivan recognizes Novian Health, Inc. with ... for Technology Innovation Leadership. Novian Health has greatly ... tumors with its proprietary technology, Novilase ® ... accurate, and easy-to-control ultrasound-guided thermo ablation device that ...
Breaking Medicine Technology:ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... NEW YORK, Jan. 13, 2011 Although 2010 brought ... healthcare reform repeal.  Investors should likely expect some volatility ... wreak havoc on healthcare reform, either through a repeal ... according to analysts at Standard & Poor,s Equity Research. ...
... N.J., Jan. 13, 2011 Quest Diagnostics Incorporated (NYSE: ... information and services, announced today that it will report fourth ... for 2011 on Tuesday, January 25, before the market opens. ... discuss the results beginning at 8:30 a.m. ET on that ...
Cached Medicine Technology:S&P Equity Research Issues Health Care Sector Predictions for 2011 2S&P Equity Research Issues Health Care Sector Predictions for 2011 3S&P Equity Research Issues Health Care Sector Predictions for 2011 4S&P Equity Research Issues Health Care Sector Predictions for 2011 5S&P Equity Research Issues Health Care Sector Predictions for 2011 6Quest Diagnostics to Release Fourth Quarter and Full Year 2010 Financial Results 2
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... N.J. (PRWEB) September 02, 2014 ... technologies and development solutions for drugs, biologics and ... of its strategic partner, Eli Lilly’s growth, it ... packaging lines at its Philadelphia Clinical Supply Center ... syringe packaging capabilities in its clinical supply facility ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... of nanotechnology in diagnosing, treating and/or prevention of ... applied for treating cardiovascular, neurological, and oncology diseases. ... of knowledge pertaining to various nanoparticles, their medical ... There still exists considerable scope for research in ...
(Date:9/2/2014)... JOSE, CA (PRWEB) September 02, 2014 ... computing and collaboration, announces partnership with NTT DoCoMo ... iPad business customers. Splashtop Business Lite is included ... Lite is a remote desktop software that empower users ... anywhere. Splashtop has garnered over 18 million users ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will ... tu vida! Get Up! Get Moving!®. This event promotes Hispanic ... wellness for people of all ages and all sizes. The ... be held at Kiest Park Recreation Center, 3080 S. Hampton ... , “Since 2007, we have partnered with National Alliance for ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... are becoming common everywhere. Only last fortnight it was reported ... 15 ft during a joyride and sustained grievous injuries in ... ,But for a tree branch which checked her ... first aid facilities available, it was reported. ,Now ...
... with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage ... to this initial agreement, Delmont Laboratory will supply bulk ... the final packaging in China. ,CBPC will ... to be signed. This product requires a clinical study ...
... fill their prescriptions while traveling abroad need to be cautious ... the AAPS National Biotechnology Conference. ,Unlike approved ... internationally. Therefore, consumers should not assume that a branded product ... the same or similar brand name in other counties. ...
... seven billion dollar (5.2 billion euro) negligence suit against ... as the US giant demanded the charges be ... early setback when the court rejected a request to ... Babs Kwewumi adjourned the trial to July 20. ...
... announces that it has completed its acquisition of ... for approximately $600 million on April 4, 2007. ... owns the patents for Electrochemiluminescence (ECL) technology and ... diagnostics field into new market segments such as ...
... called the world's first prototype of an artificial hand with ... up a raw egg. ,Squse, a Kyoto-based ... 400-gramme (14 ounce) hand with five human-sized fingers with artificial ... ,"So far, robots have an image of helping people do ...
Cached Medicine News:Health News:Girls Feet Severed in Amusement Park Accident 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 3
... SINON is a Q-switched ... wavelength of 694 nm. High ... Pulses - This combination of ... pulses in Q-switched mode effectively ...
... an in vitro immunoassay intended for the qualititive ... antigen. It is indicated for use as an ... conjunction with cystoscopy or when prescribed for in ... FDA for prescription home use in February 1999. ...
... connect an infusion bag ... and then to a ... to conduct urodynamics studies. ... Medical Technologies infusion pumps. ...
... Used for cystometry and urethral ... allows for faster filling of the ... readings. Dual lumen catheter construction allows ... cystometry is performed. Triple lumen catheter ...
Medicine Products: